Therapeutic Asset Ratings

461 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Calaspargase Pegol Lung Disease	Pfizer	P2	CCC (53)
Calaspargase Pegol Non-small Cell Lung Cancer, Squamous	Pfizer	P2	CCC (53)
Cytosin-Arabinosid Carcinoma	Pfizer	P2	CCC (53)
Cytosin-Arabinosid Lung Disease	Pfizer	P2	CCC (53)
Cytosin-Arabinosid Non-small Cell Lung Cancer, Squamous	Pfizer	P2	CCC (53)
Daunorubicin Carcinoma	Pfizer	P2	CCC (53)
Daunorubicin Lung Disease	Pfizer	P2	CCC (53)
Daunorubicin Non-small Cell Lung Cancer, Squamous	Pfizer	P2	CCC (53)
Enzalutamide Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Enzalutamide Liposarcoma	Pfizer	P2	CCC (53)
ETOPOSIDE Lung Disorder	Pfizer	P2	CCC (53)
ETOPOSIDE Non-small Cell Lung Cancer, Squamous	Pfizer	P2	CCC (53)
Fludarabine Lung Disease	Pfizer	P2	CCC (53)
FULVESTRANT Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Hycamtin Medulloblastoma	Pfizer	P2	CCC (53)
Irinotecan Rhabdoid Tumor	Pfizer	P2	CCC (53)
Letrozole Lung Adenocarcinoma	Pfizer	P2	CCC (53)
Letrozole Liposarcoma	Pfizer	P2	CCC (53)
MIDAZOLAM Lung Adenocarcinoma	Pfizer	P2	CCC (53)
MIDAZOLAM Liposarcoma	Pfizer	P2	CCC (53)
Palbociclib Diffuse Intrinsic Pontine Glioma	Pfizer	P2	CCC (53)
PEGASPARGASE Carcinoma	Pfizer	P2	CCC (53)
PEGASPARGASE Lung Disease	Pfizer	P2	CCC (53)
PEGASPARGASE Non-small Cell Lung Cancer, Squamous	Pfizer	P2	CCC (53)
pf-07248144 Castration-Resistant Prostate Carcinoma	Pfizer	P2	CCC (53)

Showing 176 to 200 of 461 assets